1. Formelli F, Zaccheo T, Mazzoni A, Isetta AM, Casazza AM, Di Marco A: Antitumour activity and pharmacokinetics of medroxyprogesterone acetate in experimental mammary tumour systems. In: Cavalli F, McGuire WL, Pannuti F, Pellegrini A, Robustelli Della Cuna G (eds) Proceedings of the International Symposium on Medroxyprogesterone Acetate. Excerpta Medica, Princeton, 1982, pp 47–62
2. Danguy A, Legros N, Leclercq G, Heuson JC: Effects of medroxyprogesterone acetate on the development of dimethyl-benzanthracene-induced mammary tumours: possible modes of action. In: Cavalli F, McGuire WL, Pannuti F, Pellegrini A, Robustelli Della Cuna G (eds) Proceedings of the International Symposium on Medroxyprogesterone Acetate. Excerpta Medica, Princeton, 1982, pp 63–76
3. Zaccheo T, Casazza AM, Di Salle E, Pollini C, Di Marco A: Combined and sequential treatment using FCE 21336, a new prolactin-lowering drug, and medroxyprogesterone acetate (MPA) in DMBA-induced tumors in rats. Eur J Cancer Clin Oncol 20: 1193–1197, 1984
4. Tominaga T, Yoshida Y, Kitamura M, Kosaki G: Effective sequential administration of tamoxifen and medroxyprogesterone acetate for 7,12-dimethylbenz[a]anthracene-in-duced rat mammary tumors in relation to hormone receptors. Jpn J Cancer Res (Gann) 76: 1120–1125, 1985
5. Racca S, Conti G, Crispino A, Gallo E, Di Carlo F: Effects of medroxyprogesterone acetate on DMBA-induced mammary tumors. Chemoterapia 4: 236–238, 1985